UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors

    • Categories

    Archives

    Nov

    23

    Epilepsia Publishes Interim Results of Open-Label Extension Study of FINTEPLA® (fenfluramine) Oral Solution in Patients with Lennox-Gastaut Syndrome (LGS)

    Read More Share:linkedin| twitter| email

    Nov

    22

    UCB Submits Response to FDA Complete Response Letter for Bimekizumab

    Read More Share:linkedin| twitter| email

    Nov

    21

    Nicole Williams’ Has an Impact From Investments to Innovation to Inclusion

    Read More Share:linkedin| twitter| email

    Nov

    17

    Shaping the Future of Psoriatic Arthritis Care in Rural Settings

    Read More Share:linkedin| twitter| email

    Nov

    14

    UCB announces U.S. FDA acceptance of new drug application and EMA MAA validation for zilucoplan for the treatment of generalized myasthenia gravis in adult patients

    Read More Share:linkedin| twitter| email

    Nov

    11

    United for Veterans and our Employees Who Serve

    United for Veterans is one of UCB’s Employee Resource Groups (ERGs) focused on veterans and veteran supporters. United for Veterans leverages the combined strength of UCB’s veterans and veteran supporters by encouraging through shared experiences, celebrating veterans’ diversity, inspiring professional development, and honoring veteran communities through servant leadership opportunities while fulfilling our company goals and diversity, equity, and inclusion ambition.

    Read More Share:linkedin| twitter| email

    Nov

    10

    Bimekizumab Demonstrated Sustained Clinical Responses to Week 52 in Phase 3 Studies in Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis

    Read More Share:linkedin| twitter| email

    Nov

    09

    Moving the Conversation Forward in Rheumatology – UCB at ACR Convergence 2022

    Read More Share:linkedin| twitter| email

    Nov

    08

    UCB Reinforces Commitment to Rheumatology With 15 Abstracts Including New Late-Breaking Data at ACR Convergence 2022

    Read More Share:linkedin| twitter| email

    © 2009 - 2020 UCB, Inc., Atlanta. All rights reserved.
    USPR-CORP-0115-00003(2)